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Abstract The therapeutic role of mediastinal radiotherapy
and stem cell transplantation (SCT) in lymphoblastic
lymphoma (LL) remains controversial. In a risk-oriented
design, we adopted a flexible treatment program in which
(1) patients with persistent mediastinal abnormality, evalu-
ated by post-induction computed chest tomography, re-
ceived mediastinal irradiation; and (2) those with
persistence of minimal residual disease (MRD), evaluated
by MRD analysis of the bone marrow, underwent SCT.
Twenty-eight out of 30 patients (T-lineage, n=24; B-
lineage, n=6) achieved a complete response. Of 21 patients
with mediastinal mass, 13 (62%) achieved a complete
response after chemotherapy alone, while 6 (28.5%)
required additional irradiation. Eleven patients were evalu-
ated for MRD: 6 were negative and 5 positive. On the basis
of MRD findings and clinical risk characteristics, 14
patients underwent SCT, 13 received maintenance chemo-
therapy, and 1 had local radiotherapy. Five patients
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relapsed. Among the 14 non-irradiated patients with T-LL,
the mediastinal recurrence rate was only 7%. After a
median follow-up of 3.9 years, 21 patients who responded
were alive without recurrence (75%). The projected 5-year
survival, disease-free survival, and relapse rate were 72%,
77%, and 18%, respectively. This program induced high
remission and survival rates, indicating the feasibility and
the benefits potentially associated with a selective,
response-oriented policy of mediastinal irradiation and a
concurrent MRD-based strategy to assign adult LL patients
to SCT.
Keywords Lymphoblastic lymphoma .Mediastinal
irradiation .Minimal residual disease . Stem cell
transplantation
Introduction
Lymphoblastic lymphoma (LL) is a rare tumor of B or,
more often, T lymphoblasts that frequently involves the
mediastinum (more than 70% of cases of T-LL). It is related
closely to acute lymphoblastic leukemia (ALL), from which
it can be differentiated by the predominant extramedullary
involvement in LL and bone marrow infiltration by blast
cells of less than 25% [1, 2]. In adults, LL is treated with
regimens that are used to treat ALL (ALL-type regimens)
[3–9], but these regimens give inferior results compared
with those achieved normally in children [10–12]. One
relevant issue is the role of mediastinal tumors in the failure
of treatment, and debate persists as to whether all patients
should undergo mediastinal irradiation or only those with
residual disease post-induction. In a German study, the rate
of mediastinal tumor progression was high, despite the use
of intensive chemotherapy and early mediastinal irradiation
[8]. With the Hyper-CVAD regimen from the M.D.
Anderson Cancer Center (MDACC), the use of higher-
dose irradiation (30–39 Gy) as an adjunct seems to reduce
the incidence of relapse, although mediastinal progression
still occurs [9]. A second issue related to treatment is
whether the identification of prognostic factors, which are
used to define patients with high-risk characteristics who
are eligible for hematopoietic stem cell transplantation
(SCT), can be used to predict outcome. All the risk factors
studied so far have failed to predict outcome with respect to
current ALL-type chemotherapy regimens [3]. In ALL, the
analysis of minimal residual disease (MRD) through
immunophenotypic or molecular techniques, which can
identify as few as 1×10−5 leukemic cells in normal-looking
bone marrow, provides a powerful means to predict relapse
accurately in individual patients [13]. Currently, the
intensification of treatment with SCT is considered to be
the best treatment option for patients with ALL who are
MRD-positive after induction plus early consolidation
therapy. With respect to LL, the prognostic role of MRD
has been studied in detail in childhood [14] but not in adult
disease. In the present study, we adopted an ALL-type
chemotherapy program together with the flexible applica-
tion of early mediastinal irradiation. Only patients with
residual tumors post-induction, as assessed by a computed
tomography (CT) scan of the mediastinum, received
mediastinal irradiation. MRD in the bone marrow was
analyzed concurrently with the mediastinal evaluation to
gather evidence of occult disease contamination of the
marrow. We used the information obtained as an indicator
of the risk of relapse and a tool to decide between post-
consolidation maintenance therapy (MRD-negative
patients) and SCT (MRD-positive patients).
Patients and methods
Patients
Between the years 2000 and 2008, 30 consecutive adult
patients with untreated LL were enrolled in the Northern
Italy Leukemia Group (NILG) Protocol 09/00 (Table 1)
[15]. The diagnosis was established by histological exam-
ination in accordance with the WHO criteria [1, 2]. The
clinical evaluation included bone marrow biopsy, the
examination of cerebrospinal fluid, a full blood count, and
biochemistry, which included serum lactate dehydrogenase,
plus CT scans of the chest and abdomen. Clinical staging
was performed in accordance with the Ann Arbor System.
Because of the difficulty in obtaining adequate diagnostic
specimens for a detailed immunophenotypic and cytoge-
netic/genetic analysis for risk stratification in many LL
patients, the high-risk (HR) subset included all the patients
with T-LL, those with pro-B CD10-negative B-LL, and
those achieving late complete remission (CR). Only the
patients with pre-B CD10-positive B-LL were defined
standard-risk (SR) in this study.
Analysis of MRD
Patient-specific molecular probes were identified using
biopsy samples or bone marrow in patients with >5%
infiltrating blast cells, and were tested for sensitivity and
specificity as reported previously [15]. One or two probe(s)
were used per patient, with the aim of achieving a
sensitivity of at least 10−4 in the RQ-PCR (reverse
quantitative polymerase chain reaction) assay. MRD in the
bone marrow was examined at baseline and at predefined
time points (TP) post-induction (before cycles 4, 6, and 8; i.e.,
weeks [w] 10, 16, and 22). TheMRD findings were entered in
an MRD risk model to distinguish between MRD-positive
74 Ann Hematol (2012) 91:73–82
(MRDpos) and MRD-negative (MRDneg) patients (MRDneg,
MRD-negative at w22 and negative/low positive <10−4 at
w16; MRDpos, any other MRD combination).
Early treatment (phase A) and MRD/risk-oriented therapy
(phase B)
The NILG Protocol 09/00 (ClinicalTrials.gov identifier:
NCT00358072) has been reported previously [15], and is
detailed as Online Resource 1. Briefly, the induction plus
early consolidation therapy (phase A) consisted of a
prednisone–cyclophosphamide pre-phase (T-LL only) [16]
followed by eight blocks of chemotherapy administered
over 25 weeks, in association with central nervous system
(CNS) chemo-radioprophylaxis after cycle 3. Cycles 4 and
7 included high-dose (HD) methotrexate and cytarabine.
Autologous blood stem cells that had been primed with G-
CSF were collected after cycle 4. Mediastinal irradiation
(24 Gy planned) was delivered after cycle 2 only to patients
with residual disease as confirmed by CT scan (>2 cm).
Post-consolidation therapy (phase B) was MRD/risk-oriented.
After completion of MRD analysis, and regardless of clinical
risk class, MRDneg cases were allocated to standard
maintenance therapy, whereas MRDpos patients were eligible
to allogeneic SCT, or, when a compatible related or family
unrelated donor was not found, to autologous HD therapy
followed by maintenance. The HD sequence included up to
four consecutive “hypercycles” with HD etoposide, 6-
mercaptopurine, and melphalan (cycles 1 and 3), and HD
methotrexate and cytarabine (cycles 2 and 4), each followed
by the reinfusion of 1–2×106/kg CD34+ blood stem cells.
The MRDneg patients received a 2-year maintenance
program with 6-mercaptopurine daily and methotrexate
weekly, which was reinforced monthly during the first year
by the addition of vincristine–prednisone (even cycles) and
cyclophosphamide (odd cycles). Patients for whom the
results of MRD analysis were not available were scheduled
to receive phase B therapy on the basis of their clinical risk
class (SCT if HR, maintenance if SR).
Response evaluation and statistics
The response to treatment was evaluated after cycle 1 in
accordance with the method of Cheson et al. [17]. This
included full clinical assessment, bone marrow biopsy in
patients with prior involvement, and CT scans of the chest
and abdomen as indicated in the protocol. CR was defined
as the disappearance of any clinical manifestation of LL, as
confirmed by imaging procedures, which included the
recovery of normal marrow morphology (blasts <5%) in
patients with infiltrating blast cells. A late CR was
characterized by the achievement of a response only after
cycle 2 and/or the need for mediastinal irradiation, whereas
non-responsiveness indicated the persistence of LL. Overall
survival (OS) was calculated from the date of diagnosis to
death, and disease-free survival (DFS) from the date of CR
Characteristics Total (%) (n=30) B-LL (n=6) T-LL (n=24) P value
Gender (male/female) 17/13 2/4 15/9 n.s.
Age (years), median (range) 27 (16–57) 26 (16–28) 32 (16–57) 0.04
Hemoglobin <12 (g/dL), no. (%) 5 (17) 1 (17) 4 (17) n.s.
Platelets <120 (×109/L), no. (%) 0 0 0 –
Elevated LDH, no. (%) 18 (60) 1 (17) 17 (71) 0.01
Serum LDH (U/L), median (range) 530 (145–2,787) 298 (145–535) 620 (266–2,787) 0.006
Stage, no. (%)
I 5 (17) 3 (50) 2 (8)
II 8 (27) 0 8 (33)
III 1 (3) 0 1 (4)
IV 16 (53) 3 (50) 13 (54)
B symptoms, no. (%) 8 (27) 0 8 (33) n.s.
Mediastinal involvement, no. (%) 21 (70) 1 (17) 20 (83) 0.001
Bone marrow involvement, no. (%) 12 (40) 2 (33) 10 (42) n.s.
Extranodal involvement,a no. (%) 14 (47) 4 (67) 10 (42) n.s.
Pleural effusion 9 0 9 (37)
Pericardial effusion 3 0 3 (12)
Skin 2 2 (33) 0
Ovary/testis 2b 2b (33) 0
Thyroid 1 0 1 (4)
High risk subset,* no. (%) 26 (87) 2 (33) 24 (100)
Table 1 Diagnostic
characteristics of the patients
n.s. not significant
a excluding mediastinum and
bone marrow
b one each
*indicates eligibility to SCT by
protocol design (modifiable by
MRD study)
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to relapse at any site or death in CR. The cumulative
incidence of relapse (CIR) was calculated from the date of
CR to recurrence. The DFS and survival curves were
plotted by the Kaplan–Meier method and compared by the
log-rank test.
Results
Patient characteristics
As shown in Table 1, the median age of the patients was
27 years, 17 patients were male, 80% had T-LL, and 70%
presented with a mediastinal mass. Infiltration of the bone
marrow by LL was documented in 40%, whereas no patient
had CNS involvement. After the diagnostic work-up, 13
patients (43%) were classified as stage I/II (n=5/8) and 17
(57%) as stage III/IV (n=1/16).
Treatment response and mediastinal irradiation
Twenty-eight patients (93%) achieved CR and 2 had
refractory T-LL (Table 2). Of the 21 patients with an
enlarged mediastinum, 13 (62%) entered CR, and 8 (38%)
had a residual tumor as defined by CT scan. Seven of the
latter eight patients were irradiated and six achieved CR.
All patients who achieved CR underwent successful
collection of blood stem cells (median CD34+ cells 13.3×
106/kg, range 2–55.3).
Analysis of MRD
Molecular probes for MRD-based risk definition were
identified in 11 of 14 patients studied (Table 3). In 3
patients, no specific probe was detectable, and in 14 other
CR patients, no diagnostic specimen was available for
probe generation. A molecular probe was obtained
successfully in one patient with normal marrow mor-
phology (UPN 289). This finding was not inconsistent
with the study methods, because rearrangements of the T-
cell receptor gene can be detected with as few as 1%
lymphoblasts [18]. The sensitivity of the probe was ≥10−4
in six patients (54.5%). However, given that low-
sensitivity probes can be used to detect high levels of
MRD, all patients were studied, principally to define those
at greater risk of relapse. Interestingly, two of five patients
with normal bone marrow on the basis of standard
morphological criteria showed a positive PCR signal at
baseline (TP0), which indicated subclinical dissemination
of tumor cells into the marrow. Eventually, six patients
were classified as MRDneg (55%) and five as MRDpos
(45%). Four of the five MRDpos patients were defined as
such by the use of low-sensitivity probes, as opposed to
only one of the six MRDneg patients. Autologous blood
stem cells collected after cycle 4 were available for MRD
analysis in seven patients. Apheretic products were
MRDneg in all three MRDneg patients, and MRDpos in
two of four MRDpos patients (below quantitative range in
one, Table 3).
MRD and risk-oriented therapy
All six MRDneg patients received maintenance therapy.
Four of the five MRDpos patients received SCT, whereas
one underwent maintenance therapy owing to the presence
of a psychiatric disorder. Among the 17 patients with
undefined MRD status, 15 received phase B therapy and 2
did not because of refusal and medical reasons, respective-
ly. Phase B consisted of an allograft or the HD autologous
therapy in 9 out of 12 patients classified HR (75%), and
maintenance in 2 of 3 patients classified SR (67%).
Maintenance and HD autologous therapy were instead
prescribed to the remaining three HR and one SR patients,
respectively, based on patient and/or physician's choice.
Eventually, the protocol adherence rate for phase B was
75% (21 out of 28 patients), in relation to the MRD study
results and the clinical risk classification in 10 and 11
patients, respectively.
Table 2 Outcome to induction therapy according to LL subtype, presence of mediastinal mass, and mediastinal irradiation
Outcome T-LL B-LL ALL
Med+(n=20) Med−(n=4) Med+(n=1) Med−(n=5) Med+(n=21) Med−(n=9) Total (n=30)
CR, no. (%) 18 (90) 4 (100) 1 (100) 5 (100) 19 (90.5) 9 (100) 28 (93)
After CHT 13 (65) 4 (100) 0 5 (100) 13 (62) 9 (100) 22 (73)
After CHT plus MRT 5 (25) – 1 (100) – 6 (28.5) – 6 (20)
Refractory, no. (%) 2 (10) 0 0 0 2 (9.5) 0 2 (7)
After CHT 1 (5) – – – 1 (4.75) 0 1 (3.5)
After CHT plus MRT 1 (5) – – – 1 (4.75) 0 1 (3.5)
CR complete remission, Med mediastinal mass, CHT chemotherapy, MRT mediastinal radiation therapy (computed tomography-oriented)
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Duration of remission and survival
With a median follow-up period of 3.9 years (range, 0.8–
9.2+ years), 22 patients (73%) who responded were alive at
the time of writing: 21 in first CR and 1 in second CR.
Post-remission failure was due to recurrence (n=5, 18%) in
either the bone marrow (B-LL, n=1; T-LL, n=3; one
irradiated and two non-irradiated patients) or mediastinum
(n=1, non-irradiated T-LL patient), or to other malignancy
(n=2, 7%; acute myeloid leukemia [AML] and large B-cell
lymphoma, respectively). Of the five patients who relapsed,
four died and one is alive in second CR after allogeneic
SCT. The estimated OS rate at 5 years was 72%, 83% for
B-LL, and 69% for T-LL. The 5-year DSF rate was 77%,
83% for B-LL, and 71% for T-LL; the CIR probability at
5 years was 18% (Fig. 1).
Prognostic analysis
The probability of OS and DFS was not affected signifi-
cantly by any of the factors examined (Table 4). The
achievement of a molecular remission was associated with a
better outcome; DFS at 5 years increased from 60% in the
MRDpos group to 80% in the MRDneg group, although the
difference was not statistically significant owing to the
small number of patients (Fig. 2). The DFS was 83% and
81% in patients who received allogeneic SCT and mainte-
nance therapy, respectively, and 50% in those who
underwent the HD autologous phase. The CIR was 8%
and 17% in the groups who received maintenance therapy
and allogeneic SCT, respectively, compared with 37% in
the group given HD autologous therapy. The outcome of
the 11 MRD-studied patients is detailed in Table 3. The
outcome of the 12 HR patients treated outside the MRD
study varied according to cell subset and treatment. Of the
ten T-LL patients, three fared well following allogeneic
SCT, six received HD autologous therapy (with one CR
death, two relapses, and three patients alive and well), and
the last one relapsed after maintenance. Both HR B-LL
patients did well on maintenance, and all three SR B-LL
patients experienced a prolonged DFS (two maintenance,
one HD autologous therapy).
Discussion
We analyzed the long-term outcome of 30 adult patients
with LL who were enrolled prospectively in the NILG
study 09/00. LL is rare in adult patients, the most recent
prospective series dealing with 27–34 total patients (a
Table 3 MRD study and clinical outcome
Patient
UPN
(age/sex)
Diagnosisa
(stage)
Bone marrow
(% blast cells)
MRD study MRD study results MRD risk
class
Treatment Outcome
Sample Probe(s) Probe
sensitivity
TP0 TP1 TP2 TP3 PB
241 (36/M) T-LL (IV) Abn (10) BM TCRD 10−4 pos neg neg neg NA MRDneg CHT A/W (61+)
TCRD 10−3 pos neg neg neg
909 (25/M) T-LL (IV) Abn (10) BM TCRD 10−5 pos neg neg neg NA MRDneg CHT A/W (21+)
57 (43/F) T-LL (I) N Med TCRD 10−5 NA neg neg neg neg MRDneg CHT A/W (89+)
74 (36/F) T-LL (II) N PL TCRG 10−3 NA neg neg neg neg MRDneg CHT A/W (99+)
913 (23/M) T-LL (II) N LN TCRB 10−4 pos neg neg neg neg MRDneg CHT A/W (42+)
TCRB 10−3 pos neg neg neg neg
104 (46/M) T-LL (IV) Abn (16) LN TCRG 10−5 NA low–pos NA neg NA MRDneg CHT D (35,4)b
TCRD 10−5 NA low–pos NA neg
12 (22/M) T-LL (IV) Abn (15) BM TCRG 10−3 pos NA pos pos low–pos* MRDpos CHT A/W (112+)
331 (17/M) T-LL (IV) N PL TCRG 10−4 NA NA pos neg pos MRDpos Allo-SCT A/W (50+)
TCRG 10−3 NA NA neg neg neg
289 (30/M) T-LL (I) N BM TCRB 10−3 pos pos pos pos neg MRDpos Allo-SCT A/W (56+)
375 (38/F) T-LL (IV) Abn (22) BM TCRG 10−3 pos pos pos pos NA MRDpos Allo-SCT REL/D (19)
TCRG 10−2 pos pos pos pos
22 (16/F) B-LL (IV) Abn (10) BM TCRG 10−3 pos NA pos pos neg MRDpos HD-auto REL/D (29)
N normal, Abn abnormal, BM bone marrow, Med mediastinum, LN lymphnode, PL pleural effusion, TCR T-cell receptor (B beta, G gamma, D delta)
gene rearrangement, pos positive ≥10−4 , low–pos positive <10−4 ; neg negative, NA not available, PB peripheral blood stem cell harvest (*positivity
below quantitative range) MRDneg , MRD-negative; MRDpos , MRD-positive, CHT chemotherapy, allo-SCT allogeneic stem cell transplantation, HD-auto
high-dose therapy (“hypercycles”) with autologous support, A/W alive and well in first complete remission, REL relapse, D death (survival in months)
a T-LL or B-LL
b Patient died of secondary AML
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figure comparable to our study), with only a single study
from Germany including exceptionally 45 patients [8, 9, 19,
20]. In the NILG program, induction chemotherapy was
integrated with early mediastinal irradiation in patients with
suboptimal tumor regression, whereas the molecular anal-
ysis of MRD was used for the first time in adult LL to
decide between SCT and standard maintenance for post-
induction therapy. The general results reflected the high rate
of CR that can be attained in LL with ALL-like regimens
[4–6, 8–12] in contrast to regimens for non-Hodgkin
lymphoma [7, 21].
The rate of 93% for CR and the projected 5-year OS and
DFS rates of 72% and 77%, respectively, compare
favorably with those obtained in recent German and
MDACC studies, which reported rates of 91–93% for CR
and 5-year DFS rates between 62% and 66% [8, 9].
Although ALL-like induction regimens can be associated
with pronounced morbidity, none of our patients died early,
during induction chemotherapy, as compared with 8% of
patients with ALL who were treated with the same schedule
[15]. Two patients (7%) did die in CR from other
neoplasms. Remission mortality in LL has been reported
previously to range from 5% to 9%, which included
secondary AML [8, 9]. The median ages for the patients
in the German and MDACC series were 25 and 28 years,
respectively, which were similar to the median age in our
study (27 years). The distribution of other clinical charac-
teristics was also similar, and no patient in our series had
CNS disease, as in the German study but in contrast to the
MDACC study (9%). In the present study, all patients
received prophylactic cranial irradiation (18 Gy) plus 12
triple intrathecal injections, and none suffered from CNS
relapse. In studies that employed five to eight intrathecal
injections with or without cranial irradiation, the rate of
CNS relapse was <5% [8, 9]. The lowest rate of CNS
relapse (1.8%) was observed in one study that employed
higher-dose methotrexate (5 g/m2 instead of 1–1.5 g/m2)
plus intrathecal prophylaxis [22].
In LL, a key therapeutic issue is how mediastinal tumors,
which are both the cause and the site of early recurrence,
can be managed best [3]. In the current series, 20 out of 24
patients with T-LL (83%) had mediastinal involvement, but
only a proportion of them (n=8, 35%) had residual disease
post-induction, as confirmed by a positive CT scan, that
required additional radiation therapy to increase the overall
response rate in this patient cohort from 62% to 82%.
Given that mediastinal recurrence occurred in only 1 out of
14 non-irradiated patients in CR (7%) to confirm the
adequacy of the present risk-adapted consolidation regimen
(with or without SCT) in patients with chemosensitive
mediastinal disease, we recommend the use of selective
irradiation on the basis of the early CT result. The omission
of mediastinal irradiation in patients who have been
identified as responsive to chemotherapy through the CT
scan would reduce the delay in the application of
chemotherapy, which is theoretically of benefit in patients
with extensive extranodal and marrow involvement. More-
over, long-term cardio-pulmonary complications of medi-
astinal irradiation could be avoided in a significant
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proportion of younger patients, more than 50% according to
our results [23]. To improve this strategy, positron emission
tomography (PET) could be used to optimize the evaluation
of residual mediastinal disease in T-LL [24] and refine the
decision criteria for irradiation. In the German study, 41 out
of 45 patients with T-LL (91%) had mediastinal involve-
ment, and all received radiation therapy at a dose of 24 Gy
[8]. Seven out of 42 patients who achieved CR (17%)
suffered a relapse in the mediastinum. As a result, the
radiotherapy dose was increased to 36 Gy in the subsequent
trial; the results of which are awaited. Notably, a regimen
for childhood LL that avoided irradiation and used a higher
dose of methotrexate (5 g/m2) resulted in a low rate of
mediastinal relapse (7%) [11]. Leukemic T-lymphoblasts
are exquisitely sensitive to methotrexate concentrations of
approximately 65 μmol/l, which are achievable in vivo with
5 g/m2 methotrexate infusions [25, 26]. As a consequence,
this type of systemic intensification therapy should be
evaluated further for the optimal prevention of mediastinal
recurrence in T-LL.
Prognostic factors for adult LL are poorly understood. In
our series, immunophenotype and clinical stage did not
have a significant effect, although survival was slightly
better in patients with B- rather than T-LL, as reported
previously [27, 28], and in patients with stage I/II (85%)
rather than stage III/IV (62%) disease. Given that, in
patients with ALL, MRD is the best available means to
predict relapse and to select high-risk patients for allogeneic
SCT [15], we elected to investigate the use of this
parameter in adult LL. Up to 30% of patients with LL are
at risk of failing to respond to the chemotherapy regimen
used [3]; hence, we looked for persistent signs of MRD in
the bone marrow, which denote the chemo-resistant
dissemination of LL and an increased risk of relapse. The
protocol was designed such that patients who were found to
be positive for MRD were switched from standard
chemotherapy to allogeneic SCT (or alternatively to HD
therapy with autologous stem cell support). Past studies
have confirmed the therapeutic efficacy of SCT in adults
with LL [19, 29, 30], with survival rates of 55–72%,
which almost overlap with the best results obtained with
chemotherapy. Although allogeneic SCT might no longer
be a routine choice in the current era of improved
chemotherapy results [3, 8, 9], it remains the most
effective treatment modality for acute lymphoid malig-
nancies beyond CR1 [31]. Hence, it is appropriate to
Overall survival Disease-free survival
Prognostic factors No. Probability at 5 years P value No. Probability at 5 years P value
Age, years
≥30 13 0.67 0.69 12 0.73 0.88
<30 17 0.75 16 0.74
Gender
Male 17 0.62 0.19 15 0.63 0.26
Female 13 0.85 13 0.85
Phenotype
B 6 0.83 0.49 6 0.83 0.57
T 24 0.69 22 0.71
Mediastinum
Not involved 9 0.60 0.65 9 0.60 0.54
Involved 21 0.76 19 0.79
Mediastinum involved
With effusiona 9 0.89 0.29 8 0.87 0.50
Without effusion 12 0.67 11 0.73
LDH
Normal 11 0.61 0.43 10 0.67 0.74
Abnormal 18 0.78 17 0.76
Clinical stage
I/II 13 0.85 0.20 13 0.77 0.81
III/IV 17 0.62 15 0.70
Bone marrow
Not involved 18 0.83 0.13 17 0.82 0.25
Involved 12 0.54 11 0.59
Table 4 Univariate prognostic
analysis
a pleural and/or pericardic
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consider allogeneic SCT in MRD-positive patients, who
are at the highest risk of relapse.
Only a small proportion (39%) of the patients with LL
underwent MRD analysis, in contrast to 79% of the adult
patients with ALL who were treated concurrently with the
same protocol [15]. In many cases, this can be explained by
the lack of an adequate biopsy specimen, together with the
low incidence of bone marrow involvement (40% of the
patients, all with blast cells <25%), which, by itself,
precluded the identification and testing of probes. Aside
from this, the survival of the MRDneg patients, who were
treated with chemotherapy, was better than that of the
MRDpos patients, whereas MRDpos patients who received
allogeneic SCT fared better than those who were unable to
have an allograft. Thus, it appears, in keeping with the
rationale of the study, that the analysis of MRD allows the
early identification of the relatively few patients with LL
who are highly likely to fail chemotherapy, and in whom
SCT can have a greater chance of success. In this regard,
patients with MRD levels ≥10−4 after early consolidation
have the highest risk of recurrence [13, 15]. Low-sensitivity
probes (≥10−3), which are unsuitable for the confirmation
of a negative status for MRD, are nonetheless useful to
detect high levels of residual disease, and should be
employed to identify candidates suitable for salvage therapy
by SCT. Given that multiparametric flow cytometry allows
the degree of marrow contamination by LL cells to be
evaluated in almost all patients with a sensitivity of at least
10−4 [14], this technique should be integrated with, if not
substituted for, the molecular analysis of MRD in future
studies. The analysis of MRD also confirmed that bone
marrow of normal morphology can harbor LL cells at
diagnosis. Although this concept is not new [32], and has
been emphasized recently in childhood T-LL [14], these
findings underline the importance of the analysis of MRD
during the diagnostic process. This analysis should increase
the accuracy of clinical staging even in patients with early-
stage disease and without apparent bone marrow involve-
ment. While SCT was a successful choice in MRDpos
patients, standard consolidation therapy plus maintenance
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Fig. 2 Kaplan–Meier estimates of disease-free survival according to (a) immunophenotype, (b) clinical stage, (c) mediastinal involvement
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resulted in a high chance of cure (DFS 80% at 5 years) in
the MRDneg subset. Extending this observation in a large
patient number could also allow to assess the need for
prolonged maintenance therapy, that could not be even
necessary in T-LL patients who achieve an early medias-
tinal response and maintain an MRDneg status. This
perspective should be best evaluated with the support of
CT/PET analysis and an optimized MRD monitoring.
The prospective NILG study confirmed the favorable
therapeutic outcome of an ALL-type regimen in adults with
LL. This treatment, in combination with response-oriented
mediastinal irradiation, reduced the incidence of mediasti-
nal recurrence to only 4.5% (1/22 patients with T-LL in
CR). Concurrently, the molecular analysis of MRD allowed
patients at higher risk of progression to be identified, which
both improved the classification of clinical risk and offered
the best rationale for the selective application of SCT. The
combination of CT/PET scans with flow cytometry analysis
of MRD to assess response in the two most critical sites for
LL, the mediastinum and bone marrow, could provide
another advance in the management of adult LL.
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